Paul L Wood, PhD
Director, Metabolomics Unit, Professor & Associate Dean for Research

College of Veterinary Medicine
Lincoln Memorial University
Cumberland Gap Pkwy, Harrogate, TN
Tel: 423-869-6666


Canadian MRC Postdoctoral Fellowship NIMH (Lab of Preclinical Pharmacology), Washington, DC (Dr. E. Costa and Dr. D. Cheney) : Study of the peptidergic modulation of septal-hippocampal cholinergic neurons. (1977-1979)
Ph.D. Pharmacology Queen`s University; Ontario, Canada (Dr. R.J. Boegman): Axonal Transport in the Dystrophic Hamster (1973-1977)
B.Sc. Hons., Biology/Biochemistry Trent University; Ontario, Canada (1969-1973)


Paul L Wood has completed his Ph.D. from Queen’s University and postdoctoral studies from the NIMH. He is the director of the Metabolomics Unit at Lincoln Memorial University and is professor of pharmacology and physiology. He has published more than 280 peer-reviewed papers.

Research Interest

The Metabolomics Unit utilizes high-resolution mass spectrometric analytical platforms to discover biomarkers of disease, of disease progression, and of diseases response to therapy. The metabolomics and lipidomics data obtained with these platforms also has to potential to define new therapeutic targets for drug development. Ongoing projects in the Metabolomics Unit include:

  • Lipidomics of lung diseases
  • Lipidomics of parasitic infections
  • Lipidomics of fetal maturation
  • Sperm lipidomics
  • Lipidomics of Rodococcusequi
  • Lipidomics and metabolomics of ovine paratuberculosis
  • Lipidomics and metabolomics of leptospirosis
  • Cancer lipidomics
  • Lipidomics for postmortem interval determination
  • Lipidomics and metabolomics of extracellular matrix degradation

Scientific Activities

Grant Review Committees and Advisory Committees

National High Magnetic Field Lab (FSU) External Advisory Committee: 2009-present

NIA: 2009-2010

Canada Foundation for Innovation: 2006-2007

ADMHA (Behavioral Neurobiology Subcommittee): 1987-1992

NIDA (Drug Abuse Biomedical Research Review Committee): 1987-1989


Mouse cuprizone model of demyelination. NSERC, 2008-2009 ($350,000). P. Wood, PI.

Novel therapeutics for chronic pain. SBIR (1R43NS51150-1) 2004-2006. ($150,000)

Agents for the treatment of memory and learning disorders. NIH 1992-1995. A Kozikowski, PI. ($569,024).

Operating Grant, Canadian MRC, 1983-1984 ($45,000) Cortical Opiate Receptors

Maintenance Grant, Canadian MRC, 1982-1984 ($30,000)

Operating Grant, Canadian MRC, 1981-193 (eith Dr. P. Etienne, $70,000) Neurochemical and Clinicopathological Studies of the Substantia Innominata and Septum in Alzheimer's Disease

Operating Grant, Canadian MRC, 1981-19831 ($70,000) Cortical and Hippocampal Cholinergic Pathways: Regulatory Inputs

Establishment Grant, Fonds de la Recherche en Sante du Quebec, 1981-1982 ($20,000)

  • S-1A receptor agonists and S2 receptor antagonists
  • Partial BZ agonists, inverse BZ agonists and BZ agonist/antagonist
  • Neurosteroid agonists (Ganaxalone) Competitive (Selfotel) and non-competitive
  • NMDA receptor antagonists
  • NMDA-asociated glycine receptor agonists (Milacemide; D-cycloserine)
  • NMDA-asociated glycine receptor antagonists (Licostinel)
  • Anti-apoptosis compounds
  • Atypical neuroleptics and DA autoreceptor agonists
  • Tryptamine antagonist
  • Adenosine agonists
  • Kappa opiate agonists
  •  Enkephalinase inhibitors
  •  Sodium and calcium (Ziconotide) channel blockers
  •  Non-peptide BK-1 antagonists
  •  Inhibitors of MAPK activation
  •  NO donor / SOD mimetics
  •  Aldehyde trapping agents
  •  Plasmalogen precursors

Preclinical development (toxicology, ADME, safety pharmacology, CMC, DMF and formulation), Phase 1 and Phase 2 clinical trials.



  1. Wood, P.L. & Boegman, R.J.C. (1975) Increased rate of rapid axonal transport in vitamin E deficient rats. Brain Res. 84:325-328.
  2. Boegman, R.J., Wood, P.L. & Pinaud, L. (1975) Increased axoplasmic flow associated with pargyline under conditions which induce a myopathy. Nature 253:51-52.
  3. Wood, P.L. & Boegman R.J. (1975) Increased axoplasmic flow in experimental ischemic myopathy. Exp. Neurol. 48:136-141.


  1. Boegman, R.J. & Wood, P.L. (1976) Monoamines as possible mediators in the regulation of fast axoplasmic flow. J. Neurochem. 26:737-740.


  1. Malthe-Sorenssen, D., Wood, P.L., Cheney, D.L., & Costa, E. (1978) Modulation of the turnover rate of acetylcholine by intraventricular injections of thyrotropin-releasing hormone, somatostatin, neurotensin and angiotensin II. J. Neurochem. 31:685-691.
  2. Wood, P.L., Malthe-Sorenssen, D., Cheney, D.L., & Costa, E. (1978) Increase of hippocampal acetylcholine turnover rate and the stretching-yawning syndrome elicited by alpha-MSH and ACTH. Life Sciences 22:673-678.
  3. Wood, P.L., Cheney, D.L., & Costa, E. (1978) Modulation of the turnover rate of hippocampal acetylcholine by neuropeptides: Possible site of action of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and somatostatin. J. Pharmacol. Exp. Ther. 209:97-103.
  4. Wood, P.L. & Cheney, D.L. (1978) The effects of muscarinic receptor blockers on the turnover rate of acetylcholine in various regions of the rat brain. Can. J. Physiol. Pharmacol. 57:404:411.
  5. Cheney, D.L., Robinson, S.E., Malthe-Sorenssen, D.,Wood, P.L., & Costa, E. (1978) Regulation of hippocampal cholinergic neurons by dopaminergic synapses in septum. IN: E. Usdin (ed) Catecholamines: Basic and Clinical Frontiers. Pergamon Press, N.Y. pp1062-1064,
  6. Robinson, S.E., Malthe-Sorenssen, D., Wood, P.L., & Commissiong, J. (1978) Dopaminergic control of the septal- hippocampal cholinergic pathway. J. Pharmacol. Exp. Ther. 208:476-479.
  7. Cheney, D.L., Robinson, S.E., Malthe-Sorenssen, D., Wood, P.L., Commissiong, J.W., & Costa, E. (1978) Regulation of the cholinergic septal-hippocampal pathway: Role of dopaminergic septal afferents. Adv. Pharmacol. Therap. 5:241-250.


  1. Wood, P.L., Moroni, F., Cheney, D.L., & Costa, E. (1979) Cortical lesions modulate turnover rates of acetylcholine and gamma-aminobutyric acid. Neurosci. Letters 12:349-354.
  2. Wood, P.L., Cheney, D.L., & Costa, E. (1979) A prolactin action on dopamine terminals modulates acetylcholine metabolism in striatum and hippocampus. J. Neurochem. 34:1053-1057.
  3. Wood, P.L., Cheney, D.L., & Costa, E. (1979) An investigation of whether septal gamma-aminobutyrate-containing interneurons are involved in the reduction in the turnover rate of acetylcholine elicited by substance P and -endorphin in the hippocampus. Neuroscience 4:1479-1484.
  4. Wood, P.L., Peralta, E., Cheney, D.L., & Costa, E. (1979) The turnover rate of ACh in the hippocampus after lesion of hippocampal pyramidal cells with kainic acid. Neuropharmacology 18:519-524.
  5. Revuelta, A.V., Cheney, D.L., Wood, P.L., & Costa, E. (1979) GABAergic mediation in the inhibition of hippocampal acetylcholine turnover rate elicited by delta 9-tetrahydrocannabinol. Neuropharmacology 18:525-530.


  1. Hong, J.S., Wood, P.L., Gillin, J.C., Yang, H.Y.T., & Costa, E. (1980) Changes of hippocampal met-enkephalin content after recurrent motor seizures. Nature 285:231-232.
  2. Hong, J.S., Wood, P.L., Gillin, J.C. , Yang, H.Y.T., & Costa, E. (1980) Recurrent convulsions and hippocampal met(5)-enkephalin content. Adv. Biochem. Psyco-pharmacol. 22:385-397.
  3. Wood, P.L. & Stotland, L.M. (1980) Actions of enkephalin, mu and partial agonist analgesics on acetylcholine turnover in rat brain. Neuropharmacology 19:975-982.
  4. Wood, P.L., Stotland, L.M., Richard, J.W. & Rackham, A. (1980) Actions of mu, kappa, sigma, delta and agonist/antagonist opiates on striatal dopaminergic function. J. Pharmacol. Exp. Ther. 215:697-703.
  5. Wood, P.L. & Boegman, R.J. (1980) Axonal transport of [3H]cholesterol derived from [3H]leucine in the sciatic nerve. FEBS Letters 115:110-112.


  1. Boegman, R.J. & Wood, P.L. (1981) Axonal transport in dystrophic hamsters. Can. J. Physiol. Pharmacol. 59:202- 204.
  2. Wood, P.L., Cheney, D.L. & Costa, E. (1981) Interactions of neuropeptides with cholinergic septal-hippocampal pathway: Indication for a possible trans-synaptic regulation. Adv. Behav. Biol. 25:715-722.
  3. Wood, P.L. & Rackham, A. (1981) Actions of kappa, sigma and partial mu narcotic receptor agonists on rat brain acetylcholine turnover. Neurosci. Letters 23:75-80.
  4. Wood, P.L., Rackham, A. & Richard, J. (1981) Spinal analgesia: Comparison of the mu agonist morphine and the kappa agonist ethylketazocine. Life Sci. 28:2119-2125.
  5. Rackham, A., Therriault, M., & Wood, P.L. (1981) Substance P: Evidence for spinal mediation of some behavioral effects. Neuropharmacology 20:753-755.
  6. Hudgin, R.L., Charleson, S.E., Zimmerman, M., Mumford, R, & Wood, P.L. (1981) Enkephalinase: Selective peptide inhibitors. Life Sci. 29:2593-2601.
  7. Haubrich, D.R., Williams, M., Yarbrough, G.G. & Wood, P.L. (1981) 2-Chloroadenosine inhibits brain acetylcholine turnover in vivo. Can. J. Physiol. Pharmacol. 59:1196-1198.
  8. Wood, P.L., Charleson, S.E., Lane, D. & Hudgin, R.L. (1981) Multiple opiate receptors : Differential binding of mu, kappa and delta agonists. Neuropharmacology 20:1215-1220.
  9. Rackham, A., Wood, P.L., & Hudgin, R.L. (1981) Kyotorphin (tyrosine-arginine): Further evidence for enkephalin release. Life Sci. 30:1337-1342.


  1. Wood, P.L. & Charleson, S. (1982) High affinity [3H]ethylketazocine binding: Evidence for specific kappa receptors. Neuropharmacology 21:215-219.
  2. Wood, P.L. & Peloquin, A. (1982) Increases in choline levels in rat brain elicited by meclofenoxate. Neuropharmacology 21:349-354.
  3. Wood, P.L. (1982) Multiple opiate receptors: Support for unique mu, delta and kappa sites. Neuropharmacology 21:487-497.
  4. Wood, P.L. (1982) A selected ion monitoring assay for dopamine and its metabolites using negative chemical ionization. Biomed. Mass Spec. 9:302-306.
  5. Lal, S., Nair, N.P.V., Iskander, H.L., Etienne, P. Wood, P.L., Schwartz, G, & Guyda, H. (1982) Effect of domperidone on apomorphine-induced growth hormone secretion in normal men. J. Neural trans. 54:75-84.
  6. Wood, P.L. (1982) Phasic enkephalinergic modulation of nigrostriatal dopamine metabolism: Potentiation with enkephalinase inhibitors. Eur. J. Pharmacol. 82:119-120.
  7. Wood, P.L. (1982) Actions of GABAergic agents on dopamine metabolism in the nigrostriatal pathway of the rat. J. Pharmaol. Exp. Ther. 222:674-679.
  8. Wood, P.L., Etienne, P., Lal, S., Gauthier, S., Cajal, S., & Nair, N.P.V. (1982) Reduced lumbar CSF somatostatin levels in Alzheimer`s disease. Life Sci. 31:2073-2079.
  9. Wood, P.L., Richard, J.W. & Thakur, M. (1982) Mu opiate isoreceptors: Differentiation with kappa agonists. Life Sci. 31:2313-2317.
  10. Nair, N.P.V., Lal, S., Iskander, H.I., Etienne, P., Wood, P.L., & Guyda, H. (1982) Effect of sulpiride an atypical neuroleptic, on apomorphine-induced growth hormone secretion. Brain Res Bull. 8:587-591.
  11. Wood, P.L. & Richard, J.W. (1982) GABAergic regulation of the subtantia innominata-cortical cholinergic pathway. Neuropharmacology 21:969-972.
  12. Wood, P.L., Nair, N.P.V. & Bozarth, M. (1982) Striatal 3-methoxytyramine as an index of dopamine release: Effects of electrical stimulation. Neurosci. Letters 32:291-294.
  13. Wood, P.L., Richard, J.W., Pilapil, C., & Nair, N.P.V. (1982) Antagonists of excitatory amino acids and cyclic guanosine monophosphate in cerebellum. Neuropharmacology 21:1235-1238.
  14. Suranyi-Cadotte, B.E., Wood, P.L., Nair, N.V.P. & Schwartz, G. (1982) Normalization of platelet [3H]imipramine binding in depressed patients during remission. Eur. J. Pharmacol. 85:357-358.
  15. Wood, P.L. & Richard, J.W. (1982) Morphine and nigrostriatal function in the rat and mouse: Role of nigral and striatal opiate receptors. Neuropharmacology 21:1305-1310.
  16. Wood, P.L., Etienne, P. Lal, S. & Nair, N.P.V. (1982) GABAergic regulation of nigrostriatal neurons: Coupling of benzodiazepine and GABA receptors. Prog. Neuro-Psychopharmacol. Biol. Psych. 6:471- 474.
  17. Robitaille, Y. Wood, P.L., Etienne, P., Lal, S., Finlayson, M.H., Gauthier, S., & Nair, N.P.V. (1982) Reduced cortical choline acetyltransferase activity in Gerstmann-Straussler syndrome. Prog. Neuro-Psychopharmac. Biol. Psych. 6:529-531.
  18. Lal, S., Nair, N.P.V., Iskandar, H.I., Thavundayil, J.X., Etienne, P., Wood, P.L. & Guyda, H. (1982) Drug-induced growth hormone and prolactin responses in schizophrenia research. Prog. Neuro-Psychopharmacol. Biol. Psych. 6:631-637.


  1. Wood, P.L., Suranyi-Cadotte, B., Schwartz, G. & Nair, N.P.V. (1983) Platelet [3H]imipramine binding and red blood cell choline in affective disorders. Indications of heterogenous pathogenesis. Biol. Psychiat. 18:715-719.
  2. Wood, P.L. & Pilapil, C. (1983) Kappa opiate receptor sites: Unique heat stability in vitro. Eur. J. Pharmacol. 88:281-282.
  3. Wood, P.L., Nair, N.P.V., Lal, S. & Etienne, P. (1983) Buspirone: A potential atypical neuroleptic. Life Sci. 33:269-273.
  4. Wood, P.L. & Pasternak, G.C. (1983) Specific mu-2 isoreceptor regulation of nigrostriatal neurons: in vivo evidence with naloxonazine. Neurosci. Letters 37:291-293.
  5. Yassa, R., Schwartz, G & Wood, P.L. (1983) Lithium intraerythrocyte levels in tardive dyskinesia: A preliminary report. Biol. Psychiat. 18:825-828.
  6. Suranyi-Cadotte, B.E., Wood,P.L., Schwartz, G. & Nair, N.P.V. (1983) Altered platelet [3H]imipramine binding in schizoaffective and depressive disorders. Biol. Psychiat. 18:923-928.
  7. Wood, P.L., Sanschagrin, D., Richard, J.W. & Thakur, M. (1983) Multiple opiate receptor affinities of kappa and agonist/antagonist analgesics: In vivo assessment. J. Pharmacol. Exp. Ther. 226:545-550.
  8. Wood, P.L., McQuade, P., Richard, J.W. & Thakur, M. (1983) Agonist/antagonist analgesics and nigrostriatal dopamine metabolism in the rat: Evidence for receptor dualism. Life Sci. 33:759-762.
  9. Pilapil, C. & Wood,P.L. (1983) [3H]SKF-10047 binding to rat brain membranes: Evidence for kappa isoreceptors. Life Sci. 33 (Suppl. I):263-265.
  10. Lal, S., Nair, N.P.V., Iskandar, H.I., Wood, P.L., Etienne, P. & Guyda, H. (1983) Clinical studies on the dopamine receptor mediating apomorphine-induced growth hormone secretion. IN Neuropeptides, Neurotransmitters and Regulation of Endocrine Processes. F.Endroczi (ed), Publ. House Hung. Acad. Sci.,Budapest pp 431-442.
  11. Wood, P.L., Suranyi-Cadotte, B.E., Nair, N.P.V., LaFaille, F. & Schwartz, G. (1983) Lack of association of platelet [3H]imipramine binding sites and serotonin uptake in control and depressed patients. Neuropharmacology 22:1211-1214.
  12. Wood P.L. (1983) Opiate regulation of CNS dopaminergic pathways: Methodology, receptor types, regional variations and species differences. Peptides 4:595-601.
  13. Wood, P.L. McQuade, P.S., Etienne, P., Lal, S. & Nair, N.P.V. (1983) Differential actions of classical and atypical neuroleptics on mouse nigrostriatal neurons. Prog. Neuro- Psychopharmacol. Biol. Psychiat. 7:765-768.
  14. Wood, P.L., Nair, N.P.V., Etienne, P., Lal, S., Gauthier, S., Robitaille, Y., Bird, E.D., Palo, J., Haltia, M. & Paetau, A. (1983) Lack of cholinergic deficit in the neocortex in Pick`s disease. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 7:725-728.
  15. Wood, P.L. (1983) Opioid receptor affinities of kappa agonists, agonist/antagonists and antagonists in vitro and in vivo. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 7:657-662.
  16. Lal, S., Nair, N.P.V., Eugenio, H., Thavundayil, J., Lizondo, E., Wood, P.L., Etienne, P. & Guyda, H.I. (1983) Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 7:537-544.
  17. McQuade, P.S. & Wood, P.L. (1983) The effects of beta- phenylethylamine on tyramine and dopamine metabolism. Prog Neuro-Psychopharmacol. Biol. Psychiat. 7:755-760.
  18. Wood, P.L., Etienne, P., Lal, S., Nair, N.P.V., Finlayson, M.H., Gauthier, S., Palo, J., Haltia, M., Paetau, A. & Bird, E.D. (1983) A post-mortem comparison of the cortical cholinergic system in Alzheimer`s disease and Pick`s disease. J. Neurol. Sci. 62:211-217. Montpellier. pp138-144.


  1. Wood, P.L., Pilapil, C., Thakur, M. & Richard, J.W. (1984) Win 44,441: A stereospecific and long-acting narcotic antagonist. Pharmaceut. Res. 1:46-48.
  2. Wood, P.L., Stotland, L.M. & Rackham, A (1984) Opiate receptor regulation of acetylcholine metabolism: Role of mu, delta, kappa and sigma narcotic receptors. IN Dynamics of Neurotransmitter Function. I. Hanin (ed). Raven Press. N.Y. pp 99-107.
  3. Wood, P.L., Hudgin, R.L. & Rackham, A. (1984) Neuropharmacology of kappa and agonist/antagonist analgesics. Symposium: Quo Vadis? Kappa receptors and their ligands. Clin Midy Press. Montpellier. pp206-214.
  4. Wood, P.L. & Hudgin, R.L. (1984) Enkephalinase inhibitors: In vitro and in vivo pharmacology. Symposium: Quo Vadis? Analgesia and enkephalinases. Clin Midy Press. Montpellier. pp138-144.
  5. Wood, P.L. (1984) Animal models in analgesic testing. IN Analgesics: Neurochemical, Behavioral and Clinical Perspectives. M.J. Kuhar & G.W. Pasternak (eds) Raven Press. N.Y. pp175-194.
  6. Wood, P.L., Pilapil, C., LaFaille, F., Nair, N.P.V. & Glennon, R.A. (1984) Unique [3H]tryptamine binding sites in rat brain: Distribution and pharmacology. Arch. Int. Pharmacodyn. Ther. 268:194-201.
  7. Wood, P.L. (1984) Kappa agonist analgesics: Evidence for mu-2 and delta opioid receptor antagonism. Drug Dev. Res. 4:429-435.
  8. Nair, N.P.V., Lal, S., Thavundayil, J.X., Wood, P.L., Etienne, P., & Guyda, H.I. (1984) CCK-33 antagonizes apomorphine- induced growth hormone secretion and increases basal prolactin levels in man. Neuropeptides 4:281-291.
  9. Wood, P.L., Loo, P., Braunwalder, A., Cheney, D.L. (1984) In vitro characterization of benzodiazepine agonists, antagonists, inverse agonists and agonist/antagonists. J. Pharmacol. Exp. Ther. 231:572-576.
  10. Cadotte,B., Quirion, R., McQuade, P.S., Nair, N.P.V., Schwartz, G., Mosticyan, S. & Wood, P.L. (1984) Platelet [3H]imipramine binding: A state-dependent marker in depression. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 8:737-741.
  11. Wood, P.L., Loo, P., Braunwalder, A & Cheney, D.L. (1984) In vitro characterization of agonist, antagonist, inverse agonist and agonist/antagonist benzodiazepines. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 8:785-788
  12. Lal, S., Wood, P.L., Kiely, M.E., Etienne, P., Gauthier, S., Stratford, J., Ford, R.M., Dastoor, D. and Nair, N.P.V. (1984) CSF acetylcholinesterase in dementia and in sequential samples of lumbar CSF. Neurobiol. Aging 5:269-274.
  13. Wood, P.L. & McQuade, P. (1984) Ciclindole and flucindole: Novel tetrahydrocarbazolamine neuroleptics. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 8:773-777.
  14. Suranyi-Cadotte,B., Quirion, R., McQuade, P.S., Nair, N.P.V., Schwartz, G., Mosticyan, S. & Wood, P.L. (1984) Platelet [3H]imipramine binding: A state-dependent marker in depression. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 8:737-741.
  15. Wood, P.L., Loo, P., Braunwalder, A & Cheney, D.L. (1984) In vitro characterization of agonist, antagonist, inverse agonist and agonist/antagonist benzodiazepines. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 8:785-788
  16. Lal, S., Wood, P.L., Kiely, M.E., Etienne, P., Gauthier, S., Stratford, J., Ford, R.M., Dastoor, D. and Nair, N.P.V. (1984) CSF acetylcholinesterase in dementia and in sequential samples of lumbar CSF. Neurobiol. Aging 5:269-274.


  1. Wood, P.L. (1985) In vivo evaluation of mu, delta and kappa opioid receptor agonists on spinal 5-HT metabolism in the rat. Neuropeptides 5:319-322.
  2. Wood, P.L. (1985) N-Tetrahydrofurfuryl benzomorphans: Comparison of a kappa and agonist/antagonist analgesic. Neuropeptides 5:323-326.
  3. Farnell, B.J., Crapper McLachlan, D.R., Baimbridge, K., De Boni, U., Wong, L. and Wood, P.L. (1985) Calcium metabolism in aluminum encephalopathy. Exp. Neurol. 88:68-83.
  4. Wood, P.L. & Cheney, D.L. (1985) Gas chromatography-mass fragmentography of amino acids. Neuromethods 3:51-80.
  5. Lal, S., Barriga, C., Wood, P.L., Suranyi-Cadotte, B., Nair, N.P.V. and Arnoff, A. (1985) Red cell choline in Korsakoff psychosis. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 9:629- 632.
  6. Lal, S., Nair, N.P.V., Liely, M.E., Suranyi-Cadotte, B.E., Wood,P.L., Stratford, J., Ford, R.M. and Guyda, H. (1985) Other neurotransmitters or neuromodulators in psychiatry. In. Brain Neurotransmitters and Psychiatry. A. Villeneuve (ed) Astra, Toronto. pp 62-69.
  7. Wood, P.L., Martin, L.L. and Altar, C.A. (1985) [3H]Tryptamine receptors in rat brain. In. Neuropsychopharmacology of the Trace Amines. ed. A.A. Boulton, L. Maitre, P.R. Bieck and P. Reiderer. Humana Press, Clifton, N.J. pp 101-114.


  1. Nair, N.P.V., Lal, S., Eugenio, H., Lizondo, E., Thavundayil, J.X., Wood, P.L., Etienne, P. and Guyda, H. (1986) CCK-8 antagonizes apomorphine-induced growth hormone secretion in normal subjects. Horm. Metabol. Res. 18:53-55.
  2. Pasternak, G.W. and Wood, P.L. (1986) Minireview: Multiple mu opiate receptors. Life Sci. 38:1889-1898.
  3. Wood, P. L. (1986) Pharmacological evaluation of GABAergic and glutamatergic inputs to the nucleus basalis- cortical and the septal- hippocampal cholinergic projections. Can. J. Physiol. Pharmacol. 64: 325-328.
  4. Wood, P.L., Braunwalder, A., Bennett, D.A., Bernard, P.S., Brode, S., Petrack, B. and Cheney, D.L. (1986) Benzodiazepine receptor multiplicity : Pharmacological comparison of a full agonist, partial agonist and agonist/antagonist. IN. C. Shagrass (ed), Proceedings of the IV World Congress Biological Psychiatry. Elsevier. New York. pg 276-278.
  5. Wood, P.L. (1986) Multiple opioid receptors in the central nervous system. Neuromethods 4:329-363.
  6. Williams, M. and Wood, P.L. (1986) Receptor binding in drug discovery and development. Neuromethods 4: 543-569.
  7. Iyengar, S., Kim, H.S. and Wood, P.L. (1986) Effects of kappa opiate agonists on neurochemical and neuroendocrine indices: Evidence for kappa receptor subtypes. Life Sci. 39:637-644.
  8. Rinehart, R.K., Barbaz, B., Iyengar, S., Ambrose, F., Steel, D.J., Neale, R.F., Petrack, B., Bittiger, H., Wood, P.L. and Williams, M. (1986) Benzodiazepine interactions with central thyroid-releasing hormone binding sites: Characterization and physiological significance. J. Pharmacol. Exp. Ther. 238:178-183.
  9. Iyengar, S., Kim, H.S. and Wood, P.L. (1986) Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat. J. Pharmacol. Exp. Ther. 238:429-436.
  10. Altar, C.A., Wasley, A.M., Liebman, J., Gerhardt, S., Kim, H., Welch, J.J. and Wood, P.L. (1986) CGS 10746B: An atypical antipsychotic candidate that selectively decreases dopamine release at behaviorally active doses. Life Sci. 39:699-705.
  11. Kim, H.S., Iyengar, S. and Wood, P.L. (1986) Opiate actions on mesocortical dopamine metabolism. Life Sci. 39:2033-2036.
  12. Wood, P.L. and Iyengar, S. (1986) Kappa isoreceptors: Neuroendocrine and neurochemical evidence. NIDA Res. Monograph 71: 102-108.
  13. Wood, P.L. & McQuade, P.(1986) Substantia innominata cortical cholinergic pathway: Regulatory afferents. Adv. Behav. Biol. 30: 999-1006.
  14. Etienne, P., Robitaille, Y., Wood, P., Gauthier, S., Nair, N.P.V. and Quirion, R. (1986) Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience 19:1279-1291.
  15. Lehmann, J., McPherson, S.E., Wood, P.L. and Cheney, D.L. (1986) PCP analogs - site of action at NMDA-type receptor associated ion channels? Clin. Neuropharmacol. 9:497-499.
  16. Quirion, R., Martel, J.C., Robitaille, Y., Etienne, P., Wood, P.L., Nair, N.P.V. and Gauthier, S. (1986) Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can. J. Neurol. Sci. 13:503-510.
  17. Martin, L.L., Roland, D. M., Neale, R.F. and Wood, P.L. (1986) Structural relationships in the inhibition of [3H]tryptamine binding to rat brain membranes in vitro by phenylalkylamines. Eur. J. Pharmacol. 132:53-55.


  1. Wood, P.L., Kim, H.S. and Altar, C.A. (1987) In vivo assessment of dopamine and norepinephrine release in rat neocortex: GC-MF measurement of 3-methoxytyramine (3-MT) and normetanephrine (NMN). J. Neurochem. 48:574-579.
  2. Martin, L.L. and Wood, P.L. (1987) Effects of N-methyl-D- aspartate (NMDA) and DL-2-amino-7-phosphonoheptanoate (AP7) on mouse brain glutamate turnover. IN Excitatory Amino Acid Transmission. T.P. Hicks, D. Lodge & H. McLennan (ed) Alan R. Liss Inc. N.Y. pp 413-416.
  3. Lehmann, J., Loo, P., McPherson, S., ffrench-Mullen, J.M.H., Steel, D., Braunwalder, A., Williams, M. and Wood, P.L. (1987) NMDA- and PCP-type receptor interactions. IN Excitatory Amino Acid Transmission. T.P. Hicks, D. Lodge & H. McLennan (ed) Alan R. Liss Inc. N.Y. pp 91-98.
  4. Tsai, C., Steel, D.J., McPherson, S., Taylor, C.A., Wood, P.L. and Lehmann, J. (1987) PK 26124 is not a competitive antagonist at NMDA-type receptors. IN Excitatory Amino Acid Transmission. T.P. Hicks, D. Lodge & H. McLennan (ed) AlanR. Liss Inc. N.Y. pp 79-82.
  5. McPherson, S.E., Loo, P., Braunwalder, A. and Wood, P.L. (1987) Enhancement of the in vivo binding of [3H]flunitrazepam by the atypical neuroleptic, clozapine. Neuropharmacology 26:265 269.
  6. Lehmann, J., Schneider, J., McPherson, S., Murphy, D.E., Bernard, P., Tsai, C., Bennett, D.A., Pastor, G., Steel, D., Boehm, C., Cheney, D.L., Liebman, J.M., Williams, M. and Wood, P.L. (1987) CPP, a selective NMDA-type receptor antagonist: Characterization in vitro and in vivo. J. Pharmacol. Exp. Ther. 240:737-746.
  7. Altar, C.A., Boyar, W.C. and Wood, P.L (1987) Dopamine autoreceptor agonists including CGS 15855A decrease dopamine release and metabolism in mouse brain. Europ. J. Pharmacol. 134: 303-311.
  8. Wood, P.L.,Kim, H.S. and Marien, M.R. (1987) Intracerebral dialysis: Direct evidence for the utility of 3-MT measurements as an index of dopamine release. Life Sci. 41:1-5.
  9. Iyengar, S., Kim, H.S. and Wood, P.L. (1987) Agonist action of the agonist/antagonist analgesic butorphanol on dopamine metabolism in the nucleus accumbens of the rat. Neurosci. Lett. 77:226-230.
  10. Lal, S., Quirion, R., Lafaille, F., Nair, N.P.V., Loo, P., Braunwalder, A., Wood, P.L. & Williams, M. (1987) Muscarinic, benzodiazepine, GABA, chloride channel and other binding sites in frontal cortex in hepatic coma in man. Prog. Neuropsychopharmacol. Biol. Psychiat. 11: 243-250.
  11. Wood, P.L. and Iyengar, S. (1987) Central actions of opiates and opioid peptides: In vivo evidence for opioid receptor multiplicity. IN The Opiate Receptors (G.W. Pasternak, ed). Humana Press, Clifton, N.J. pp 307-356.
  12. Iyengar, S., Kim, H.S. and Wood, P.L. (1987) Mu, delta, kappa and epsilon opioid receptor modulation of the hypothalamic- pituitary-adrenocortical (HPA) axis: Sub-chronic tolerance studies of endogenous opioid peptides. Brain Res. 435: 220-226.
  13. Loo, P., Braunwalder, A. and Wood, P.L. (1987) Benzodiazepine receptor modulation of [35S]TBPS binding to the chloride channel. Noncompetitive inhibition of classical benzodiazepines and competitive inhibition of the partial agonist, CGS 9895, by CGS 8216. Neuropharmacology 26: 775-778.
  14. Kim, H.S., Iyengar, S. and Wood, P.L. (1987) Reversal of the actions of morphine on mesocortical dopamine metabolism in the rat by the kappa agonist MR-2034: Evidence for mu-2 opioid control of mesocortical dopaminergic projections. Life Sci. 41:1711-1715.
  15. Altar, C.A., Boyar, W.C., Oei, E. and Wood, P.L. (1987) Dopamine autoreceptors modulate the in vivo release of dopamine in the frontal, cingulate and entorhinal cortices. J. Pharmacol. Exp. Ther. 242: 115-120.
  16. Martin, L.L., Neale, R.F. and Wood, P.L. (1987) Down regulation of tryptamine receptors following chronic administration of chlorgyline. Brain Res. 419: 239-243.
  17. Wood, P.L., Steel, D., McPherson, S.E., Cheney, D.L. and Lehmann, J. (1987) Antagonism of N-methyl-D-aspartate evoked increases in cerebellar cGMP and striatal ACh release by phencyclidine receptor agonists: Evidence for possible allosteric coupling of NMDA and PCP receptors. Can J. Physiol. Pharmacol. 65: 1923-1927.
  18. Wood, P.L., Kim, H.S., Cosi, C. and Iyengar, S. (1987) The endogenous kappa agonist, dynorphin(1-13) does not alter basal or morphine-stimulated dopamine metabolism in the rat nigrostriatal pathway. Neuropharmacology 26: 1585-1588.


  1. Wood, P.L. (1988) The significance of multiple CNS opioid receptor types: A review of critical considerations relating to technical details and anatomy in the study of central opioid actions. Peptides 9: 49-55.
  2. Lehmann, J. and Wood, P.L. (1988) Interactions between the NMDA-type receptor complex and PCP recognition sites. In Sigma- and PCP-Like Compounds as Molecular Probes in Biology. (E.F. Domino and J.M. Kamenka, ed.). NPP Books, Ann Arbor. pp 251- 258.
  3. Wood, P.L., Steel, D.J., Kim, H.S., Petrack, B. and Altar, C.A. (1988) Cholecystokinin: Potential modulator of climbing and mossy fiber input to mouse cerebellar purkinje cells. J. Pharmacol. Exp. Ther. 244: 58-62.
  4. Wood, P.L., Kim, H.S., Cheney, D.L., Cosi, C., Marien M., Rao, T.S. and Martin, L.L. (1988) Constant infusion of [13C6]glucose: Simultaneous measurement of GABA and glutamate turnover in defined rat brain regions of single animals. Neuropharmacology 27: 669-676.
  5. Wood, P.L., Altar, C.A. and Kim, H.S. (1988) Presynaptic inhibition of nigrostriatal dopamine release in the mouse: Lack of cross tolerance between apomorphine, GBL and CGS 10746B. Life Sci. 42: 1503-1506.
  6. Cosi, C. and Wood, P.L. (1988) Lack of GABAergic modulation of acetylcholine turnover in the rat thalamus. Neurosci. Lett. 87: 293-296.
  7. Altar, C.A., Boyar, W.C., Oei, E. and Wood, P.L. (1988) Cholecystokinin attenuates basal and drug-induced increases of limbic and striatal dopamine release. Brain Res. 460: 76-82.
  8. Lehmann, J., Chapman, A.G., Meldrum, B.S., Hutchison, A., Tsai, C., and Wood, P.L. (1988) CGS 19755 is a potent and competitive antagonist at NMDA-type receptors in vitro and in vivo. Eur. J. Pharmacol. 154:89-93.
  9. Lehmann, J., Hutchison, A.J., McPherson, S.E., Mondadori, C., Schmutz, M., Sinton, C.M., Tsai, C., Murphy, D.E., Steel, D.J., Williams, M., Cheney, D.L. and Wood, P.L. (1988) CGS 19755, a selective and competitive NMDA-type excitatory amino acid receptor antagonist. J. Pharmacol. Exp. Ther. 246: 65-75.
  10. Wood, P.L. and Altar, C.A. (1988) Dopamine release in vivo from nigrostriatal, mesolimbic and mesocortical neurons: Utility of 3-methoxytyramine measurements. Pharmacol. Rev. 40: 163-187.
  11. Wood, P.L., Kim, H.S., Stocklin, K. and Rao, T.S. (1988) Dynamics of the striatal 3-MT pool in rat and mouse striatum: Species differences as assessed by steady-state measurements and intracerebral dialysis. Life Sci. 42: 2275-2281.
  12. Martin, L.L., Baker, G.B. and Wood, P.L. (1988) Tryptamine turnover: Effects of drugs. IN. Trace Amines: Comparative and Clinical Neurobiology. A.A. Boulton, A.V. Juorio and R.G.H. Downer (eds). Humana Press, Clifton, N.J. pp 73-102.
  13. Altar, C.A., Wasley, A.M. and Wood, P.L. (1988) Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naunyn. Schmied. Arch. Pharmacol. 338: 162-168.
  14. Lehmann, J., Tsai, C. and Wood, P.L. (1988) Homocysteic acid as a putative excitatory amino acid neurotransmitter. I. Postsynaptic characteristics at N-Methyl-D-Aspartate-type receptors on striatal cholinergic interneurons. J. Neurochem. 51: 1765-1770.


  1. Wood, P.L., Kim, H.S., Boyar, W.C. and Hutchison, A. (1989) Inhibition of rat nigrostriatal dopamine release by adenosine receptor agonists: A1 receptor mediation. Neuropharmacology 28:21-25.
  2. Iyengar, S., Hausler, A., Kim, H.S., Marien, M., Altar, C.A. and Wood, P.L. (1989) The dopamine autoreceptor agonist CGS 15855A modulates striatal dopamine metabolism and prolactin release. Neuropharmacology 28:27-31.
  3. Iyengar, S., Kim, H.S., Marien, M.M., McHugh, D. and Wood, P.L. (1989) Modulation of mesolimbic dopaminergic projections by -endorphin in the rat. Neuropharmacology 28: 123-128.
  4. Wood, P.L. and Rao, T.S. (1989) GC-MS and GC-MS/MS of monoamines, indoles, trace amines and their associated precursors and metabolites. In Mass Spectrometry of Biological Materials. C.N. McEwen and B.S. Larsen (ed) Marcel Dekker Inc., N.Y. pp 197-214.
  5. Wood, P.L. and Rao, T.S. (1989) NMDA-coupled and uncoupled forms of the PCP receptor: Preliminary in vivo evidence for PCP receptor subtypes. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 13: 519-523.
  6. Wood, P.L (1989) CCK modulation of cerebellar afferents: Dopaminergic involvement? Prog. Neuro-Psychopharmacol. Biol. Psychiat. 13: 513-518.
  7. Cheney, D.L., Lehmann, J., Cosi, C. and Wood, P.L. (1989) Determination of acetylcholine dynamics. Neuromethods 12: 443-495.
  8. Rao, T.S., Cler, J.A., Emmett, M.R., Mick, S., Iyengar, S., Contreras, P.C. and Wood, P.L. (1989) Ifenprodil and SL 82.0715 antagonize N-methyl-D-aspartate (NMDA)-coupled glycine receptor responses in vivo. Eur. J. Pharmacol. 168: 129-131.
  9. Cosi, C., Altar, C.A. and Wood, P.L. (1989) Effect of cholecystokinin on acetylcholine turnover and dopamine release in the rat striatum and cortex. Eur. J. Pharmacol. 165: 209-214.
  10. Rao, T.S., Kim, H.S., Lehmann, J., Martin, L.L. and Wood, P.L. (1989) Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. Life Sci. 45:1065-1072.
  11. Wood, P.L., Emmett, M.R., Rao, T.S., Mick, S., Cler, J. and Iyengar, S. (1989) In vivo modulation of the N-methyl-D-aspartate receptor complex by D-serine: Potentiation of ongoing neuronal activity as evidenced by increased cerebellar cGMP. J. Neurochem. 53: 979-981.


  1. Wood, P.L., Rao, T.S., Iyengar, S., Lanthorn, T., Monahan, J., Cordi, A., Vasquez, M. and Contreras, P. (1990) A review of the in vitro and in vivo characterization of the NMDA/PCP/glycine/ ion channel receptor macrocomplex. Neurochem. Res. 14: 217-229.
  2. Rao, T.S., Cler, J.A., Compton, R.P., Emmett, M.R., Mick, S., Sun, E., Iyengar, S. and Wood, P.L. (1990) Neuropharmacological characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, ligands of the N-methyl-D-aspartate (NMDA)-associated glycine receptor. Neuropharmacology 29: 305-309.
  3. Iyengar, S., Mick, S., Dilworth, V., Michel, J., Rao, T.S., Farah, J.M. and Wood, P.L. (1990) Sigma receptors modulate the hypothalamic-pituitary-adrenal (HPA) axis centrally: Evidence for a functional interaction with NMDA receptors, in vivo. Neuropharmacology. 29: 299-303.
  4. Iyengar, S. and Wood, P.L. (1989) Multiplicity and classification of opioid receptors. In Opioid Peptides, Vol 4. J.I. Szekely and K. Ramabadran (ed). CRC Press pp 115-132.
  5. Rao, T.S., Kim, H.S., Lehmann, J., Martin, L.L. and Wood, P.L. (1990) Interaction of phencyclidine receptor agonist MK-801 with dopaminergic system: Regional studies in the rat. J. Neurochem. 54: 1157-1162.
  6. Petrack, B., Emmett, M., Rao, T.S., Kim, H.S. , and Wood, P.L. (1990) Increases in rat striatal preproenkephalin mRNA levels following chronic treatment with the depot neuroleptic, haloperidol decanoate. Life Sci. 46: 687-691.
  7. Rao, T.S., Cler, J.A., Oei, E.J., Iyengar, S. and Wood, P.L. (1990) Increased release of dopamine in vivo by BMY-14802: Contrasting pattern to clozapine. Neuropharmacology 29: 503-506.
  8. Rao, T.S., Kim, H.S., Lehmann, J., Martin, L.L. and Wood, P.L. (1990) Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: Tentative evidence for PCP recognition sites not coupled to N- Methyl-D- Aspartate (NMDA) receptors. Neuropharmacology 29:225- 230.
  9. Rao, T.S., Cler, J.A., Oei, E.J., Emmett, M.R., Mick, S., Iyengar, S. and Wood, P.L. (1990) The polyamines, spermine and spermidine, negatively modulate N-methyl-D-aspartate (NMDA) and quisqualate receptor mediated responses in vivo: Cerebellar cyclic GMP measurements. Neurochem. Int. 16: 199-206.
  10. Wood, P.L., Emmett, M.R., Rao, T.S., Cler, J., Mick, S. and Iyengar, S. (1990) Inhibition of nitric oxide synthase blocks N-methyl-D-aspartate-, quisqualate-, kainate-, harmaline-and pentylenetetrazol-dependent increases in cerebellar cyclic GMP in vivo. J. Neurochem. 55:346-348.
  11. Wood, P.L., Emmett, M.R., Rao, T.S., Mick, S., Cler, J., Oei, I and Iyengar, S. (1990) In vivo antagonism of agonist actions at NMDA and NMDA-associated glycine receptors in mouse cerebellum: Studies of HA-966. Neuropharmacology 29: 675-679.
  12. Rao, T.S., Cler, J.A., Emmett, M.R., Mick, S., Iyengar, S. and Wood, P.L. (1990) BMY- 14802 antagonizes harmaline- and D-serine-induced increases in mouse cerebellar cyclic GMP: Neurochemical evidence for a sigma receptor-mediated functional modulation of responses mediated by the N-methyl-D-aspartate receptor complex in vivo. Mol. Pharmacol. 37: 978-982.
  13. Rao, T.S., Cler, J.A., Mick, S.J., Iyengar, S. and Wood, P.L. (1990) Inhibition of climbing and mossy fiber, and basket and stellate cell inputs to mouse cerebellar Purkinje cells by novel anti-ischemic agents, ifenprodil and BMY-14802. Life Sci. 47: PL1-PL5.
  14. Monahan, J.B., Biesterfeldt, J.P., Hood, W.F., Compton, R.P., Cordi, A.A., Vasquez, M.L., Lanthorn, T.H. and Wood, P.L. (1990) Differential modulation of the associated glycine recognition site by competitive N-methyl-D-aspartate receptor agonists. Mol. Pharmacol. 37:780-784.
  15. Wood, P.L., Emmett, M.R., Rao, T.S., Mick, S.J., Cler, J.A. and Iyengar, S. (1990) In vivo cerebellar cGMP responses: A model system for studies of the NMDA-associated glycine receptor. In Neurotoxicity of Excitatory Amino Acids. A. Guiudotti (ed). Raven Press. New York. pp 223-234.
  16. Rao, T.S., Contreras, P.C. and Wood, P.L. (1990) Are N-methyl-D-aspartate (NMDA) and phencyclidine (PCP) receptors always functionally coupled to each other? Neurochem. Int. 17:1-8.
  17. Iyengar, S., Dilworth, V., Mick, S., Contreras, P., Monahan, J., Rao, T.S. and Wood, P.L. (1990) Sigma receptors modulate both A9 and A10 dopaminergic neurons in the rat brain: Functional interaction with NMDA receptors. Brain Res. 524: 322-326.
  18. Rao, T.S. and Wood, P.L. (1990) Haloperidol decanoate administration induces differential tolerance to striatal and pyriform cortical dopamine metabolism. Neurosc. Res. Comm. 7: 83-88.
  19. Lal, S., Gauthier, S., Wood, P.L., Kiely, M.E., Waserman, J. and Nair, N.P.V. (1990) Red cell choline in spasmodic torticollis and in a monozygotic twin pair with tourette's syndrome. Progr. Neuro-Psychopharmacol. Biol. Psychiat. 14: 785-789.
  20. Rao, T.S., Cler, J.A.,, Mick, S.J., Emmett, M.R., Iyengar, S. and Wood, P.L. (1990) 6,7-Dinitroquinoxaline-2,3-dione and 6-nitro,7-cyanoquinoxaline-2,3-dione antagonize responses mediated by N-methyl-D-aspartate and NMDA-associated glycine recognition sites in vivo: Measurements of cerebellar cyclic GMP. Neuropharmacology 29: 1031-1035.
  21. Rao, T.S., Cler, J.A., Emmett, M.R., Mick, S.J., Iyengar, S., and Wood, P.L. (1990) Glycine, glycinamide and D-serine act as positive modulators of signal transduction at the N-methyl-D-aspartate (NMDA) receptor in vivo: Differential effects on mouse cerebellar cyclic guanosine monophosphate levels. Neuropharmacology 29:1075-1080.
  22. Rao, T.S., Cler, J.A., Mick, S.J., Dilworth, V.M., Contreras, P.C., Iyengar, S. and Wood, P.L. (1990) Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma ligand, in vivo. Neuropharmacology 29: 1191-1197.
  23. Rao, T.S., Cler, J.A., Mick, S.J., Ragan, D.M., Lanthorn, T.H., Contreras, P.C., Iyengar, D. and Wood, P.L. (1990) Opipramol, a potent sigma ligand, is an anti-ischemic agent: Neurochemical evidence for an interaction with the N-methyl-D-aspartate receptor complex in vivo by cerebellar cGMP measurements. Neuropharmacology 29:1199-1204.
  24. Sills, M.A., Bennett, D.A., Lovell, R.A., Liebman, J.M., Wood, P.L., Glaeser, B.S., Williams, M. and Hutchinson, A.J. (1990) CGS 18102A, a benzopyranopyridine anxiolytic with 5-HT1 agonist and 5-HT2 antagonist properties. Progr. Clin. Biol. Res. 361: 469-475.
  25. Bennett, D.A., Lehman, J., Bernard, P.S., Liebman, J.M., Williams, M., Wood, P.L., Boast, C.A. and Hutchinson, A.J. (1990) CGS 19755: A novel competitive N-methyl-D-aspartate antagonist with anticonvulsant, anxiolytic, and anti-ischemic properties. Prog. Clin. Biol. Res. 361: 519-524.


  1. Rao, T.S., Cler, J.A., Mick, S.J., Emmett, M.R., Farah, J.M., Contreras, P.C., Iyengar, S. and Wood, P.L. (1991) Neurochemical interactions of competitive N-methyl-D-aspartate antagonists with dopaminergic neurotransmission and the cerebellar cyclic GMP system: Functional evidence for a phasic glutamatergic control of the nigrostriatal dopaminergic pathway. J. Neurochem. 56: 907-913.
  2. Lehmann, J., Etienne, P., Cheney, D.L. and Wood, P.L. (1991) NMDA receptors and their ion channels. In Neurotransmitters and Epilepsy. R.S. Fisher & J.T. Coyle (ed). Alan R. Liss, NY. pg 147-165.
  3. Rao, T.S., Contreras, P.C., Cler, J.A., Mick, S.J., Dilworth, V.M., Iyengar, S., Monahan, J.B. and Wood, P.L. (1991) Contrasting neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with N-methyl-D-aspartate-coupled and -uncoupled PCP recognition sites. J. Neurochem. 56: 890-897.
  4. Iyengar, S., Wood, P.L., Mick, S.J., Dilworth, V., Gray, N.M., Farah, J.M., Rao, T.S. and Contreras, P.C. (1991) (+) 3-[3-hydroxyphenyl-N-(1-propyl) piperidine] selectively differentiates effects of sigma ligands on neurochemical pathways modulated by sigma receptors: Evidence for subtypes, in vivo. Neuropharmacology 30: 915-922.
  5. Emmett, M.R., Wood, P.L., Rao, T.S., Mick, S., Cler, J.A. and Iyengar, S. (1991) Actions of D-Cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 30:1167-1171.
  6. Rao, T.S., Contreras, P.C., Cler, J.A., Emmett, M.R., Mick, S.J., Iyengar, S. and Wood, P.L. (1991) Clozapine attenuates harmaline-, methamphetamine-, pentylentetrazol-, and D-serine-induced increases in mouse cerebellar cyclic guanosine monophosphate (cGMP) levels: Evidence for a functional modulation of events mediated by the N-methyl-D-aspartate (NMDA) receptor complex. Neuropharmacology 30: 557-566.
  7. Wood, P.L. (1991) Pharmacology of the second messenger, cyclic guanosine 3',5'-monophosphate, in the cerebellum. Pharmacological Reviews 43:1-25.
  8. Wood, P.L. and Rao, T.S. (1991) A review of in vivo modulation of cerebellar cGMP levels by excitatory amino acid receptors: Role of NMDA, quisqualate and kainate subtypes. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 15:229-235.
  9. Rao, T.S., Cler, J.A., Mick, S.J., Iyengar, S. and Wood, P.L. (1991) Polyamines modulate events mediated by the N-methyl-D-aspartate (NMDA) receptor complex via an ifenprodil-insensitive pathway: In vivo cerebellar cyclic GMP measurements. Neuropharmacology 30: 567-574.
  10. Wood, P.L. (1991) Role of nitric oxide in the activation of cerebellar guanylate cyclase by excitatory amino acid agonists in vivo. In Excitatory Amino Acids. B.S. Meldrum, F. Moroni, R.P. Simon and J.H. Woods (ed). Raven Press. New York. pp 317-321.
  11. Wood, P.L. and Rao, T.S. (1991) Morphine stimulation of mesolimbic and mesocortical but not nigrostriatal dopamine release in the rat, as reflected by changes in 3-methoxytyramine levels. Neuropharmacology 30:399-401.
  12. Rao, T.S., Mick, S.J., Cler, J.A., Emmett, M.R., Dilworth, V.M., Contreras, P.C., Gray, N.M., Wood, P.L. and Iyengar, S. (1991) Effects of sigma ligands on mouse cerebellar cyclic guanosine monophosphate (cGMP) levels in vivo: further evidence for a functional modulation of N-methyl-D-aspartate (NMDA) receptor complex-mediated events by sigma ligands. Brain Res. 561: 43-50.


  1. Chen, C., Kozikowski, A.P., Wood, P.L., Reynolds, I.J., Ball, R.G. and Pang, Y.-P. (1992) Synthesis and binding properties of 8a-phenyldecahydroquinolines as probes of PCP's binding confirmation. A new PCP-like compound with increased in vitro potency. J. Med. Chem. 35: 1634-1638.
  2. Wood, P.L., Ryan, R. and Li, M. (1992) Excitatory amino acid signal transduction in the hippocampus: Role of noradrenergic afferents and nitric oxide in cGMP increases in vivo. Life Sci. 51: 601-606.
  3. Dunn, R.W., Flanagan, D., Martin, L.L., Kerman, L.L., Woods, A.T., Camacho, F., Wilmot, C.A., Cornfeldt, M.L., Effland, R.C., Wood, P.L. and Corbett, R. (1992) Stereoselective (R)-enantiomer of HA-966 displays anxiolytic effects in rodents. Eur. J. Pharmacol. 214: 207-214.
  4. Wood, P.L. (1992) Interrelationships of opioid, dopaminergic, cholinergic and GABAergic pathways in the central nervous system. Handbook of Exp. Pharmacol. 104: 625-643.
  5. Wood, P.L., Li, M. and Ryan, R. (1992) NMDA-, but not kainate- or quisqualate-dependent increases in cerebellar cGMP are dependent upon monoaminergic innervation. Life Sci. 51: PL267-PL270.


  1. Rao, T.S., Gray, N.M., Dappen, M.S., Cler, J.A., Mick, S.J., Emmett, M.R., Iyengar, S., Monahan, J.B., Cordi, A.A. and Wood, P.L. (1993) Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine receptor: In vivo characterization. Neuropharmacology 32: 139-147.
  2. Lehmann, J.C., Rprocureur, D. and Wood, P.L. (1993) 7-Chlorokynurenate prevents NMDA-induced and kainate-induced striatal lesions. Brain Res. 620:1-6.
  3. Chouinard, M.L., Gaitan, D. and Wood, P.L. (1993) Presence of the N-methyl-D-aspartate-associated glycine receptor agonist, D-serine, in human temporal cortex: Comparison of normal, Parkinson and Alzheimer tissues. J. Neurochem. 61: 1561-1564.
  4. Wood, J.A., Wood, P.L., Ryan, R., Graff-Radford, N.R., Pilapil, C., Robitaille, Y. and Quirion, R. (1993) Cytokine indices in Alzheimer's temporal cortex: No changes in mature IL-1 or IL-1RA but increases in the associated acute phase proteins IL-6, 2-macroglobulin and C reactive protein. Brain Res. 629: 245-252.


  1. Wood, P.L., Emmett M.R. and Wood, J.A. (1994) Involvement of granule, basket and stellate neurons but not Purkinje or Golgi cells in cerebellar cGMP increases in vivo. Life Sci. 54: 615-620.
  2. Wood, P.L., Choksi, S. and Bocchini, V. (1994) Inducible microglial nitric oxide synthase: A large membrane pool. Neuroreport 5: 977-980.
  3. Wood, P.L. (1994) Differential regulation of IL-1 and TNF release from immortalized murine microglia (BV-2). Life Sci. 55: 661-668.
  4. Wood, P.L. (1994) Microglia: A possible cellular target for pharmacological approaches to neurodegenerative disorders. Drug News Perspectives 7: 138-157.
  5. Hyde, J.F., VanderWende, C., Wood, P.L., Kim, H.F. and Jerussi, T.P. (1994) Bilateral changes in striatal dopamine metabolism after unilateral intracarotid and intrastriatal administration of apomorphine. Brain Res. 655: 83-90.


  1. Wood, P.L. (1995) Nitric oxide as a second messenger in the cerebellum and hippocampus: in vitro and in vivo studies. S. Vincent, ed. Nitric Oxide in the Nervous System. Academic Press. pp. 103-123.
  2. Wood, P.L. (1995) Microglia as a unique cellular target in the treatment of stroke: Potential neurotoxic mediators produced by activated microglia. Neurological Res. 17: 242-248.
  3. Goodnough, D.B., Lutz, M.P. and Wood, P.L. (1995) Rapid and sensitive procedure for the separation and quantitation of D- and L-serine in rat brain using gas chromatoghraphy-mass spectrometry. J. Chromatog. B: Biomed. Appl. 667: 223-232.
  4. Wood, P.L. (1995) Minireview. The co-agonist concept: Is the NMDA-associated glycine receptor saturated in vivo? Life Sciences 57: 301-310.
  5. Ryan, R.E., Sloane, B.F., Sameni, M. and Wood, P.L. (1995) Microglial cathepsin B: An immunological examination of cellular and secreted species. J. Neurochem. 65: 1035-1045.
  6. Murray, K.D., Wood, P.L., Rosasco, C. and Isackson, P.J. (1995) A metabotropic glutamate receptor agonist regulates neurotrophin mRNA in rat forebrain. Neuroscience 70: 617-630.
  7. Wood, P.L. and Weber, W. (1995) Glycine antagonists - Development issues for use in neuroprotection. J. Grotta, L.P. Miller & A.M. Buchan, ed. Ischemic Stroke. IBC, Boston. pp. 169-186.
  8. Goodnough, D.B., Lutz, M.P. and Wood, P.L. (1995) Separation and quantitation of D- and L-phosphoserine in rat brain using FDAA (N-(2,4-dinitro-5-fluoro- phenyl)-L-alaninamide, Marfey’s reagent) by HPLC-UV. J. Chromatog. 672: 290-294.


  1. Park, C.H., Carboni, E., Wood, P.L. and Gee, K. W. (1996) Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia 16: 65-70.
  2. Hawkinson, J.E., Acosta-Burruel, M. and Wood, P.L. (1996) The metabotropic glutamate receptor antagonist L-2amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur. J. Pharmacol. 307:219 -225.
  3. Hawkinson, J.E., Acosta-Burruel, M., Kimbrough, C.L., Goodnough, D.B. and Wood, P.L. (1996) Steroid inhibition of [3H]SR 95531 binding to the GABAA recognition site. Eur. J. Pharmacol. 304: 141-146.
  4. Wood, P.L., Hawkinson, J.E. and Goodnough, D.B. (1996) Formation of D-serine from L-phosphoserine in brain synaptosomes. J. Neurochem. 67: 1485-1490.


  1. Carter, R.D., Wood, P.L., Wieland, S., Hawkinson, J.E., Belelli, D., Lambert, J.J., White, S., Wolf, H.H., Mirsadeghi, S., Tahir, S.H., Bolger, M.B., Lan, N.C. and Gee, K.W. (1997) Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3-hydroxy-3-methyl-5-pregnan-20-one), a selective, high-affinity steroid modulator of the -aminobutyric acidA receptor. J. Pharmacol. Exp. Ther. 280: 1284-1295.
  2. Edgar, D.M., Seidel, W.F., Gee, K.W., Lan, N.C., Field, G., Xia, H., Hawkinson, J.E., Wieland, S., Carter, R.B. and Wood, P.L. (1997) CCD-3693: An orally bioavailable analog of the endogenous neuroactive steroid, pregnanolone, demonstrates potent sedative hypnotic actions in the rat. J. Pharmacol. Exp. Ther. 282: 420-429.
  3. Wood, P.L. and Hawkinson, J.E. (1997) N-Methyl-D-aspartate antagonists for stroke and head trauma. Exp. Opin. Invest. Drugs 6:389-397.
  4. Wood, P.L. (1997) Current status of NMDA-associated glycine site modulators in the treatment of age-related cognitive deficits. Current Research in Alzheimer’s Disease 2: 245-250.
  5. Wieland, S., Belluzzi, J., Hawkinson, J.E., Hogenkamp, D., Upasani, R., Stein, L., Wood, P.L., Gee, K.W. and Lan, N.C. (1997) Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. Psychopharmacology 134: 46-54.
  6. Hawkinson, J.E., Acosta-Burruel, M., Ta, N.D. and Wood, P.L. (1997) Novel phosphoserine phosphatase inhibitors. Eur. J. Pharmacol.. 337: 315-324.


  1. Wood, P.L. (1998) Alzheimer’s disease: status of the neuroinflammatory hypothesis. Current Research in Alzheimer’s Disease 3: 1-8.
  2. Wood, P.L. (1998) Small molecule inducers of neurotrophic function: SR-57746A, AIT-082, and the immunophilin ligands GPI 1046 and VA 10367. Current Research in Alzheimer’s Disease 3: 141-144.
  3. Wood, P.L. (1998) Peptoid drug discovery: The choice of scaffolds for combinatorial chemistry/HTS and subsequent substitutions for parallel synthesis/lead optimization. Current Opinion Drug Discovery & Development 1: 34-40.
  4. Wood P.L. (1998) Disease-modifying drugs for Alzheimer’s disease? : Inhibitors of apoptosis, APP processing and prostaglandin formation. IDrugs 1: 675-677.
  5. Wood, P.L. (1998) NMDA Antagonists for Stroke and Head Trauma: Current status. Exp. Opinion Invest. Drug 7:1-4.
  6. Wood, P.L. (1998) Roles of CNS macrophages in neurodegeneration. IN Neuroinflammation. Mechanisms and Management. P.L. Wood (ed.). Humana Press, Totowa, NJ. pg 1-59.


  1. Vanover, K.E., Suruki, M., Robledo, S., Huber, M., Wieland, S., Lan, N.C., Gee, K.W., Wood, P.L. and Carter, R.B. (1999) Positive allosteric modulators of the GABAA receptor: Differential interaction of benzodiazepines and neuroactive steroids with ethanol. Psychopharmacology 141: 77-82.
  2. Wood, P.L. (1999) Editorial Overview: Apoptosis and Alzheimer’s disease. Currrent Opinion in CPNS Investigational Drugs 1: 325-326.
  3. Rowlett, J.K., Winger, G., Carter, R.D., Wood, P.L., Woods, J.H., and Woolverton, W. L. (1999) Reinforcing and discriminative stimulus effects of the neuroactive steroids pregnanolone and Co 8-7071 in rhesus monkeys. Psychpharmacology 145: 205-212.


  1. Vanover, K.E., Rosenzweig-Lipson, S., Hawkinson, J.E., Lan, N.C., Belluzzi, J.D., Stein, L., Barrett, J.E., Wood, P.L. and Carter, R.B. (2000) Characterization of the anxiolytic properties of the novel neuroactive steroid Co 2-6749 (GMA-839; WAY-141839; 3, 21 dihydroxy-3-trifluoromethyl-19-nor-5-pregnan-20-one), a selective modulator of -aminobutyric acidA receptors. J. Pharmacol. Exp. Ther. 295: 337-345.


  1. Floyd, R.A., Hensley, K., Forster, M.J., Kelleher-Anderson, J.A. and Wood, P.L. (2002) Nitrones as neuroprotectants and anti-aging drugs. Ann. N.Y. Acad. Sci. 959:321-329.


  1. Wood, P.L. (2003) Roles of CNS macrophages in neurodegeneration. IN Neuroinflammation. Mechanisms and Management, 2nd edition. P.L. Wood (ed.). Humana Press, Totowa, NJ. pg. 3-27.
  2. Wood, P.L. (2003) The cerebellum in AD: A Case for arrested neuroinflammation? IN Neuroinflammation. Mechanisms and Management, 2nd edition. P.L. Wood (ed.). Humana Press, Totowa, NJ. pg. 295-300.
  3. Wood P.L. (2003) Multi-functional drugs for the treatment of endothelial dysfunction in glaucoma and diabetes. IDrugs 6:360-367.


  1. Wood, P.L. (2004) The NMDA receptor complex: A long and winding road to therapeutics. IDrugs 8:229-235.
  2. Wood, PL (2004) Incremental improvements in drug therapies: The high costs and risks of pharmaceutical R&D. Current Drug Discov. 11:31-35.


  1. Moskal JR, Kuo AG, Weiss C, Wood PL, O'connor Hanson A, Kelso S, Harris RB, Disterhoft JF. (2006) GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulator. Neuropharmacology 49:1077-87.
  2. Wood, PL, Khan, AK and Moskal, JK (2006) Neurochemical analysis of amino acids, polyamines and carboxylic acids: GC-MS quantitation of tBDMS derivatives using ammonia positive chemical ionization. J. Chromatog. B 831:313-319.
  3. Wood PL, Khan MA, Kulow SR, Mahmood SA, Moskal JR. (2006) Neurotoxicity of reactive aldehydes: The concept of “aldehyde load” as demonstrated by neuroprotection with hydroxylamines. Brain Res. 1095:190-199.
  4. Wood, PL (2006) Neurodegeneration and aldehyde load: from concept to therapeutics. J Psychiatry Neurosci. 31:296-297.
  5. Wood PL, Khan MA, Moskal JR, Todd KG, Tanay VA, Baker G. (2006) Aldehyde load in ischemia-reperfusion brain injury: Neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res. 1122: 184-190.


  1. Wood, PL, Khan, AK and Moskal, JK (2007) The concept of “aldehyde load” in neurodegenerative mechanisms: Cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal and 4-aminobutanal in a retinal ganglion cell line. Brain Res. 1145: 150-156.
  2. Burgdorf J, Wood PL, Kroes RA, Moskal JR, Panksepp J. (2007) Neurobiology of 50-kHz ultrasonic vocalizations in rats: Electrode mapping, lesion, and pharmacology studies. Behav Brain Res. 182:274-283.
  3. Wood PL, Khan AK and Moskal JK (2007) Cellular thiol pools are responsible for sequestration of cytotoxic reactive aldehydes: Central role of free cysteamine and cysteine. Brain Res. 1158: 158-163.
  4. Goodenowe DB , Cook LL, Liu J, Yingshen L, Jasasinghe DA, Ahiahonu PWK, Heath D, Yamazaki Y, Flax, J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL (2007) Peripheral ethanolamine plasmalogen deficiency in Alzheimer’s: A logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 48:2485-2498.


  1. Wood PL, Khan MA, Moskal JR. (2008) Mechanism of action of the disease-modifying anti-arthritic thiol agents d-penicillamine and sodium aurothiomalate: Restoration of cellular free thiols and sequestration of reactive aldehydes. Eur J Pharmacol. 580:48-54.
  2. MacKenzie EM, Grant SL, Baker GB and Wood PL (2008) Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem. Res. 33:403-406.
  3. Wood PL, Mahmood SA, Moskal JR (2008) Antinociceptive action of GLYX-13: an N-methyl-D-aspartate receptor glycine site partial agonist.Neuroreport 19:1059-61.


  1. Pastural E, Ritchie S, Lu Y, Jin W, Kavianpour A, Khine Su-Myat , Heath D, Wood PL, Fisk M, Goodenowe DB. (2009) Novel plasma phospholipid biomarkers of autism: Mitochondrial dysfunction as a putative causative mechanism. Prostaglandins Leukot Essent Fatty Acids. 81:253-264.


  1. Wood PL, Mankidy R, Ritchie S, Heath D, Wood JA, Flax J, Goodenowe DB. (2010) Circulating plasmalogen levels and ADAS-Cog progression in Alzheimer’s patients. J. Psychiatry Neurosci. 35:59-62.
  2. Ritchie SA, Ahiahonu PWK, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan MA, Hossain M, Su-Myat K, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Shimada H, Tomonaga T, Hisahiro M, Matsushita K, Nomura F and Goodenowe DB (2010) Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: Implications for early screening and detection. BMC Cancer 8:13 (1-20)
  3. Mankidy R, Ahiahonu PW, Ma H, Jayasinghe D, Ritchie SA, Khan MA, Su-Myat KK, Wood PL, Goodenowe DB. (2010) Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study. Lipids Health Dis. 9:62-79.


  1. Wood PL, Smith T, Pelzer L, Goodenowe DB. (2011) Targeted metabolomic analyses of cellular models of Pelizaeus-Merzbacher disease reveal plasmalogen and myo-inositol solute carrier dysfunction. Lipids Health Dis. 10:102.
  2. Smith T, Ghandour MS, Wood PL. (2011) Detection of N-acetyl methionine in human and murine brain and neuronal and glial derived cell lines. J Neurochem. 118:187-194.
  3. Wood PL, Khan MA, Mankidy R, Smith T, Goodenowe DB (2011) Plasmalogen deficit: A new and testable hypothesis for the etiology of Alzheimer’s disease. Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets. (Edited by Suzanne De La Monte) InTech Open Access Publisher. ISBN 978-953-307-690-4. Pages 561-588.
  4. Wood PL, Khan MA, Smith T, Ehrmantraut, G, Jin, W, Cui, W, Braverman, NE, Goodenowe DB (2011) In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Lipids Health Dis. 10:182.
  5. Matveychuk D, Dursun SM, Wood PL and Baker GB (2011) Reactive aldehydes and neurodegenerative disorders. Bull. Clin. Psychopharmacology 21:277-288.
  6. Wood PL, Khan MA, Smith T, Goodenowe DB (2011) Cellular diamine levels in cancer chemoprevention: Modulation by ibuprofen and membrane plasmalogens. Lipids Health Dis 10:214.
  7. Wood PL, Smith T, Lane N, Khan MA, Ehrmantraut G and Goodenowe DB (2011) Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit. A new therapeutic strategy for Alzheimer’s disease. Lipids Health Dis 10:227.


  1. Wood PL (2012) Lipidomics of Alzheimer’s disease: Current status. Alzheimer’s Research & Therapy 4:5. [PMID 22293144]


  1. Wood PL and Wood JA (2013) Thiol Metabolism in Schizophrenia: Current Status. Current Psychiatry Reviews 9:136-147.
  2. Wood PL (2013) Alkylglycerol Lipid Precursors: A Review of Therapeutic Strategies for Plasmalogen Replacement. Current Organic Chemistry 17:786-792.
  3. Wood PL and Shirley NR (2013) Lipidomics Analysis of Postmortem Interval: Preliminary Evaluation of Human Skeletal Muscle. Metabolomics 3:3.


  1. Wood PL (2014) Mass Spectrometry Strategies for Targeted Clinical Metabolomics and Lipidomics in Psychiatry, Neurology, and Neuro-Oncology. Neuropsychopharmacology 39: 24-33. [PMID 23842599]
  2. Wood PL, Bravermann NE (2014) Lipidomics analysis of peroxisomal disorders: Discovery of deficits in phosphatidyglycerol levels in Rhizomelic Chondrodysplasia Type 1. J. Data Mining in Genomics and Proteomics S1:001
  3. Wood PL, Phillipps A, Woltjer RL, Kaye JA, Quinn JF (2014) Increased lysophosphatidylethanolamine and diacylglycerol levels in Alzheimer’s disease plasma. JSM Alzheimer’s Disease and Related Dementia 1:1001
  4. Wood PL, Filiou MD, Otte DM, Zimmer A, Turck CW (2014) Lipidomics reveals dysfunctional glycosynapses in schizophrenia and the G72 transgenic mouse. Schizophrenia Res 159:365-369. [PMID 25263995]
  5. Wood PL (2014) Accumulation of N-acylphosphatidylserines and N-acylserines in the frontal cortex in schizophrenia. Neurotransmitter 1:e263 [PMID 26120595]
  6. Wood PL, Wood JA (2014) Critical assessment of the status of Alzheimer’s disease Biomarkers. J. Parkinson’s disease & Alzheimer’s disease 1:4.
  7. Wood PL, Alexander RS, Felty CA (2014) Disulfiram neurotoxicity: Decrements in ethanolamine, serine, and inositol glycerophospholipids. J. Mol. Pathophysiology 3:33-37.


  1. Wood PL, Ungried G, Whitehead W, Phillipps A, Wood JA (2015) Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia. Schizophrenia Res 161:506-510 [PMID 25497445]
  2. Wildburger NC, Wood PL, Gumin J, Lichti CF, Emmett MR, Lang FL, Nilsson CL. (2015) ESI-MS/MS and MALDI-IMS localization reveal alterations in phosphatidic acid, diacylglycerol, and DHA in glioma stem cell xenografts . J. Proteome Res. 14:2511-9. [PMID 25880480]
  3. Wood PL, Barnette BL, Kaye JA, Quinn JF, Woltjer RL (2015) Non-targerted lipidomics of CSF and frontal cortex gray and white matter in control, mild cognitive impairment, and Alzheimer’s disease subjects. Acta Neuropsychiatrica 27:270-278. [PMID 25858158]
  4. Wood PL, Holderman NR (2015) Dysfunctional glycosynapses in schizophrenia: Disease and regional specificity. Schizophrenia Res. 166:235-7. [PMID 26004690]
  5. Wood PL, Medicherla S, Sheikh N, Terry B, Phillipps A, Kaye JA, Quinn JF, Woltjer RL. (2015) Targeted lipidomics of fontal cortex and plasma diacylglycerols in mild cognitive impairment (MCI). J. Alz. Dis. 48:537-546. [PMID 26402017]


  1. Wood PL, Locke VA, Herling P, Passaro A, Vigna GB, Volpato S, Valacchi G, Cervellati C, Zuliani G. (2016) Targeted Lipidomics Distinguishes Patient Subgroups in Mild Cognitive Impairment (MCI) and Late Onset Alzheimer’s Disease (LOAD).Biochem. Biophys. Acta. Clinical 5:25-28. [PMID 27051586]
  2. Cervellati C, Wood PL, Romani A, Valacchi G, Squerzanti M, Sanz JM, Ortolani B, Zuliani G. (2016) Oxidative challenge in Alzheimer's disease: state of knowledge and future needs. J Investig Med. 64:21-32. PMID: 26755810
  3. Elzinga S, Wood, PL, Adams A. (2016) Characterization of lipid and inflammatory profiles in horses with Equine Metabolic Syndrome. J. Equine Veterinary Sci. 40:49-55.
  4. Wood PL, Scoggin K, Ball BA, Lawrence L, Troedsson MH, Squires EL. (2016) Lipidomics of equine sperm and seminal plasma: Identification of amphiphilic (O-acyl)-ω-hydroxy- fatty acids. Theriogenology 86:1212-1225 [PMID 27180330]


  1. Wood PL. (2017) Non-targeted lipidomics utilizing constant infusion high resolution ESI mass spectrometry. In Springer Protocols, Neuromethods: Lipidomics Vol 125: PL Wood (ed). In press.
  2. Wood PL. (2017) Derivatization of Lipid Amines: Fluorenylmethyloxycarbonyl (FMOC). In Springer Protocols, Neuromethods: Lipidomics Vol 125: PL Wood (ed). In press.
  3. Wood PL. (2017) Derivatization of Fatty Aldehydes and Ketones: Girard’s Reagent T (GRT). In Springer Protocols, Neuromethods: Lipidomics Vol 125: PL Wood (ed). In press.
  4. Wood PL. (2017) High-Resolution Mass Spectrometry of Glycerophospholipid Oxidation Products. In Springer Protocols, Neuromethods: Lipidomics Vol 125: PL Wood (ed). In press.
  5. Wood PL, Ball BA, Scoggin K, Troedsson MT, SquiresEL. (2017) Lipidomics of equine amniotic fluid: Identification of amphiphilic (O-acyl)-ω-hydroxy-fatty acids.(submitted)
  6. Wood PL, Scoggin K, Ball BA, Lawrence L, Troedsson MH, Squires EL. (2017) Lipidomics analysis of dietary DHA on stallion spermatozoa. (submitted)
  7. Wood PL, Siljander H, Knip M. (2017) Lipidomics of human umbilical cord serum: Identification of unique sterol sulfates. (submitted)
  8. Wood PL, Tippireddy S, Feriante J (2017) Plasma lipidomics of tuberculosis patients: Altered phosphatidylcholine remodeling. (submitted)
Animal Science and Research Flyer